About Atopic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two ...

RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis - 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1] - Upadacitinib showed superiority versus dupilumab for all ranked secondary endpoints, including early improvements in itch and skin clearance[1] - The Heads Up study evaluated upadacitinib (30 mg, once daily) versus dupilumab (300 mg, ev...